Lyophilized formulation comprising GM-CSF neutralizing compound

US9833410B2 · kind B2 · utility

Assignees

• TAKEDA GMBH · DE
• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Markus Rast · Radolfzell, DE
• Wolfram Steinhilber · Stockach, DE
• Christian De Muynck · Konstanz, DE
• Gerhard Becker · Neckargemünd, DE
• Pernille Dybendal Pedersen · Copenhagen, DK
• Thomas Urbig · Birkenfeld, DE
• Thomas Boehm · Darmstadt, DE

Key dates

• Filing date: Oct 31, 2013
• Grant date: Dec 5, 2017
• Expiry date: Oct 31, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to aqueous formulations comprising at least 20 mg/ml of a compound neutralizing GM-CSF, a lyoprotectant and an amino acid and/or a buffer. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of lyophilization, storage and reconstruction. In a preferred aspect, the formulation, e.g. after reconstruction, is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.